Efficay of Physical Activity Program in PCOS Females With Fatty Pancrease and Thyroid Hypofunction
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: physical exercise program, usual care.
- Who it may be relevant to
- Registry conditions: Polycystic Ovary Syndrome, Non-Alcoholic Fatty Pancreatic Disease, Subclinical hypothyroïdism. Basic parameters: 20 years — 40 years · Female.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Egypt
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
females of polycystic ovary syndromes may complain fatty pancreaetic disorder and thyroid hypofunctions (subclinical hypothyroidism)
Detailed description
females of polycystic ovary syndromes may complain fatty pancreaetic disorder and thyroid hypofunctions (subclinical hypothyroidism) will be divided to groups (twenty female for the group). groups will be treated with levothyroxine and metformin, but one of these groups will perform aerobic treadmill walking.
Interventions
- Behavioral physical exercise program
twenty females of polycystic ovary syndromes may complain fatty pancreaetic disorder and thyroid hypofunctions (subclinical hypothyroidism)will be treated with daily dose of levothyroxine in addition to daily twotimes of 500-mg metformin, and these females will perform 50 minutes of aerobic treadmill walking hrice weekly for six month. - Other usual care
twenty females of polycystic ovary syndromes may complain fatty pancreaetic disorder and thyroid hypofunctions (subclinical hypothyroidism)will be treated with daily dose of levothyroxine in addition to daily two times of 500-mg metformin for six month.
Primary outcome measures
- Dehydroepiandrosterone [Time frame: it will be measured after 6 months]
Secondary outcome measures (12)
- ratio of leutinzing hromone to hormone of follicels stimulatting hormones [Time frame: it will be measured after 6 months]
- testesterone [Time frame: it will be measured after 6 months]
- body mass index [Time frame: it will be measured after 6 months]
- waist circumference [Time frame: it will be measured after 6 months]
- blood gluocose [Time frame: it will be measured after 6 months]
- glycated hemoglubin [Time frame: it will be measured after 6 months]
- insulin [Time frame: it will be measured after 6 months]
- thyroid stimualtined horomone [Time frame: it will be measured after 6 months]
- triglyceridess [Time frame: it will be measured after 6 months]
- low densitiy liopporotein [Time frame: it will be measured after 6 months]
- cholesteroll [Time frame: it will be measured after 6 months]
- high densitiy lipoporteins [Time frame: it will be measured after 6 months]
Eligibility criteria
Inclusion criteria
- PCOS
- fattty pancrease (non-alcoholic)
- subclinical hypothyroid (signifcant with thyroid stimauted horomone more than 10 mIU/L) and normal non-disordered free thyroxine horomones
Exclusion criteria
- cardiac disesase
- renal diseases
- respiratory disease
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Single blind
- Primary purpose
- Treatment
Study locations
Egypt · 1 center
- Cairo Unoversity — Giza
Identifiers
NCT: NCT07591246 · IRB000-14233-74